-
Camber Spine delves into biologics with portfolio expansion
Camber Spine is widening its portfolio by tapping into the biologics market. -
Biologics company adds Dr. Michael May to board
Biologics development company AgeX Therapeutics added Michael May, PhD, to its board of directors, returning it to full strength. -
Dr. Chad Kurtenbach, Sanford Health tests healing power of stem cells in osteoarthritis — 4 points
Chad Kurtenbach, MD, of Sioux Falls, S.D.-based Sanford Health is conducting a study of a stem cell treatment for patients with osteoarthritis in the knee. -
The next orthopedic revolution — Andrews' Dr. Steve Jordan on biologics
Biologics has the potential to be the next transformative tool in the orthopedic surgeon's playbook, but the field still has a ways to go before it becomes a mainstream medicinal offering. -
Health plan provides access to regenerative orthopedic procedures through partnership
Health plan provider Gilsbar entered into a partnership with interventional orthopedic clinic network Regenexx to provide beneficiaries access to reduced-cost musculoskeletal care options. -
Closing no more? Ballot initiative could grant California stem cell institute continued life
The California Institute for Regenerative Medicine was never supposed to last infinitely, but a new ballot initiative could extend its lifespan, Nature reports. -
Investor-backed company creates biologic product for spine, orthopedics — 3 insights
NanoFuse released NanoStrip, a glass synthetic biologic strip clinicians can use in spine and orthopedic procedures. -
Biologics company gets FDA approval to study adipose-derived stem cell treatment — 4 insights
The FDA approved Personalized Stem Cells' new drug application for its adipose-derived stem cell-based osteoarthritis treatment. -
Stem cell treatment targets, eradicates bone cancer metastases in mice — 4 insights
A team of UC Irvine researchers developed a mesenchymal stem cell-based treatment that can identify and kill bone cancer metastases in mice, the Daily Pilot reports. -
Dr. Adam Rivadeneyra: The promise of biologics + threat of 'bad information'
Adam Rivadeneyra, MD, a sports medicine specialist with Irvine, Calif.-based Hoag Orthopedic Institute, spoke to Becker's Spine Review about his predictions for the field of biologics. -
NanoFUSE Biologics cracks Asian market with successful procedure in Thailand
NanoFuse Biologics expanded into Asia after the successful use of its technology in a patient suffering from degenerative spine disease and osteoporosis in Thailand. -
DiscGenics tests injectable disc cell therapy for degenerative disc disease
Biotechnology company DiscGenics treated the first Utahns in its nationwide clinical study of injectable disc cell therapy for degenerative disc disease. -
California Institute for Regenerative Medicine expected to run out of money — 4 insights
The California Institute for Regenerative Medicine could close after awarding all allocated funds, The Scientist reports. -
Federal court bans Florida stem cell company from treating patients, including spinal cord injury
A federal court ordered that Sunrise, Fla.-based regenerative medicine companies US Stem Cell Clinic and US Stem Cell stop providing stem cell treatments to patients, according to the U.S. Department of Justice. -
NervGen Pharma launches MS program focusing on nerve remyelination — 3 things to know
NervGen Pharma will use its developing drug technology for spinal cord injuries in a new multiple sclerosis program. -
The path to be first — How Carmell Therapeutics could have the 1st BLA-certified regenerative offering for bone healing
Biologics therapies have the promise to revolutionize orthopedics and sports medicine, but unauthorized operators pose a serious threat to emerging therapies. -
Cerapedics appoints Patrick O'Connor to executive role — 3 insights
Orthobiologics company Cerapedics appointed Patrick O'Connor to serve as vice president of clinical and market development. -
WuXi Biologics launches commercial manufacturing through biologics center expansion — 4 insights
Chinese biologics technology company WuXi Biologics is expanding its conjugation solution center to include commercial manufacturing later this year. -
AlloSource joins Advanced Regenerative Manufacturing Institute — 3 insights
AlloSource partnered with Manufacturing USA in a new public-private initiative, the Advanced Regenerative Manufacturing Institute. -
Private investment firm invests in Royal Biologics — 4 insights
Granite Creek Capital Partners, a private investment firm in Chicago, invested in regenerative medicine company Royal Biologics.
Page 20 of 50